36,535 XNAS Volume
XNAS 28 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Todd Bazemore | SEE REMARKS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Mar 2025 | 45,200 | 45,200 | - | - | Stock Option (right to buy) | |
| Mark T. Iwicki | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2025 | 99,500 | 99,500 | - | - | Stock Option (right to buy) | |
| Mark T. Iwicki | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 7.63 per share. | 06 Jan 2025 | 5,779 | 280,076 (0%) | 0% | 7.6 | 44,094 | Common Stock |
| Mark T. Iwicki | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2025 | 22,100 | 285,855 (0%) | 0% | 0 | Common Stock | |
| R. Kim Brazzell | SEE REMARKS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2025 | 10,100 | 94,864 (0%) | 0% | 0 | Common Stock | |
| R. Kim Brazzell | SEE REMARKS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2025 | 45,200 | 45,200 | - | - | Stock Option (right to buy) | |
| R. Kim Brazzell | SEE REMARKS | Sale of securities on an exchange or to another person at price $ 7.63 per share. | 06 Jan 2025 | 2,446 | 92,418 (0%) | 0% | 7.6 | 18,663 | Common Stock |
| Todd Bazemore | SEE REMARKS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2025 | 45,200 | 45,200 | - | - | Stock Option (right to buy) | |
| Todd Bazemore | SEE REMARKS | Sale of securities on an exchange or to another person at price $ 7.63 per share. | 06 Jan 2025 | 1,993 | - | 0% | 7.6 | 15,207 | Common Stock |
| Todd Bazemore | SEE REMARKS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2025 | 10,100 | - | 0% | 0 | Common Stock | |
| Mary Reumuth | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2025 | 45,200 | 45,200 | - | - | Stock Option (right to buy) | |
| Mary Reumuth | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2025 | 10,100 | 70,287 (0%) | 0% | 0 | Common Stock | |
| Mary Reumuth | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 7.63 per share. | 06 Jan 2025 | 1,706 | 68,581 (0%) | 0% | 7.6 | 13,017 | Common Stock |
| Darius Kharabi | CHIEF BUSINESS OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2025 | 10,100 | 69,828 (0%) | 0% | 0 | Common Stock | |
| Darius Kharabi | CHIEF BUSINESS OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jan 2025 | 45,200 | 45,200 | - | - | Stock Option (right to buy) | |
| Darius Kharabi | CHIEF BUSINESS OFFICER | Sale of securities on an exchange or to another person at price $ 7.63 per share. | 06 Jan 2025 | 2,021 | 67,807 (0%) | 0% | 7.6 | 15,420 | Common Stock |
| Mark T. Iwicki | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 4.75 per share. | 26 Jun 2024 | 15,168 | 263,755 (0%) | 0% | 4.8 | 72,048 | Common Stock |
| R. Kim Brazzell | SEE REMARKS | Sale of securities on an exchange or to another person at price $ 4.75 per share. | 26 Jun 2024 | 5,489 | 83,982 (0%) | 0% | 4.8 | 26,073 | Common Stock |
| Todd Bazemore | SEE REMARKS | Sale of securities on an exchange or to another person at price $ 4.75 per share. | 26 Jun 2024 | 4,653 | 83,040 (0%) | 0% | 4.8 | 22,102 | Common Stock |
| Mary Reumuth | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 4.75 per share. | 26 Jun 2024 | 4,163 | 60,187 (0%) | 0% | 4.7 | 19,774 | Common Stock |
| Darius Kharabi | CHIEF BUSINESS OFFICER | Sale of securities on an exchange or to another person at price $ 4.75 per share. | 26 Jun 2024 | 5,158 | 59,728 (0%) | 0% | 4.8 | 24,501 | Common Stock |
| Andrew I. Koven | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 3,900 | 3,900 | - | - | Stock Option (right to buy) | |
| Andrew I. Koven | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 1,750 | 13,922 (0%) | 0% | 0 | Common Stock | |
| Gregory D. Perry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 3,150 | 3,150 | - | - | Stock Option (right to buy) | |
| Gregory D. Perry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 1,400 | 10,894 (0%) | 0% | 0 | Common Stock | |
| C. Daniel Myers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 3,150 | 3,150 | - | - | Stock Option (right to buy) | |
| C. Daniel Myers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 1,400 | 7,924 (0%) | 0% | 0 | Common Stock | |
| Howard Rosen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 3,150 | 3,150 | - | - | Stock Option (right to buy) | |
| Howard Rosen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 1,400 | 13,887 (0%) | 0% | 0 | Common Stock | |
| Mark S. Blumenkranz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 1,400 | 13,091 (0%) | 0% | 0 | Common Stock | |
| Mark S. Blumenkranz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 3,150 | 3,150 | - | - | Stock Option (right to buy) | |
| Marjan Farid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 1,400 | 7,792 (0%) | 0% | 0 | Common Stock | |
| Marjan Farid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2024 | 3,150 | 3,150 | - | - | Stock Option (right to buy) | |
| Mark T. Iwicki | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 6.09 per share. | 31 May 2024 | 7,392 | 278,923 (0%) | 0% | 6.1 | 45,017 | Common Stock |
| R. Kim Brazzell | SEE REMARKS | Sale of securities on an exchange or to another person at price $ 6.09 per share. | 31 May 2024 | 2,002 | 89,471 (0%) | 0% | 6.1 | 12,192 | Common Stock |
| Todd Bazemore | SEE REMARKS | Sale of securities on an exchange or to another person at price $ 6.09 per share. | 31 May 2024 | 2,093 | 87,693 (0%) | 0% | 6.1 | 12,746 | Common Stock |
| Mary Reumuth | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 6.09 per share. | 31 May 2024 | 1,786 | 64,350 (0%) | 0% | 6.1 | 10,877 | Common Stock |
| Darius Kharabi | CHIEF BUSINESS OFFICER | Sale of securities on an exchange or to another person at price $ 6.09 per share. | 31 May 2024 | 231 | 64,886 (0%) | 0% | 6.1 | 1,407 | Common Stock |
| Bazemore Todd | SEE REMARKS | Sale of securities on an exchange or to another person at price $ 6.74 per share. | 04 Jan 2024 | 1,405 | - | 0% | 6.7 | 9,470 | Common Stock |
| Trachtenberg Eric L. | SEE REMARKS | Sale of securities on an exchange or to another person at price $ 6.74 per share. | 04 Jan 2024 | 1,227 | 68,066 (0%) | 0% | 6.7 | 8,270 | Common Stock |
| Darius Kharabi | CHIEF BUSINESS OFFICER | Sale of securities on an exchange or to another person at price $ 6.73 per share. | 04 Jan 2024 | 1,385 | 65,117 (0%) | 0% | 6.7 | 9,321 | Common Stock |
| T. Mark Iwicki | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2024 | 14,300 | 290,854 (0%) | 0% | 0 | Common Stock | |
| Mark Iwicki T. | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2024 | 64,500 | 64,500 | - | - | Stock Option (right to buy) | |
| Brazzell Kim R. | SEE REMARKS | Sale of securities on an exchange or to another person at price $ 6.74 per share. | 04 Jan 2024 | 1,617 | 91,473 (0%) | 0% | 6.7 | 10,899 | Common Stock |
| Kim Brazzell R. | SEE REMARKS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2024 | 29,300 | 29,300 | - | - | Stock Option (right to buy) | |
| Reumuth Mary | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2024 | 20,500 | 20,500 | - | - | Stock Option (right to buy) | |
| Iwicki Mark T. | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 6.73 per share. | 04 Jan 2024 | 4,539 | 286,315 (0%) | 0% | 6.7 | 30,547 | Common Stock |
| Mary Reumuth | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 6.74 per share. | 04 Jan 2024 | 1,227 | 66,136 (0%) | 0% | 6.7 | 8,270 | Common Stock |
| Kim Brazzell R. | SEE REMARKS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2024 | 6,500 | 93,090 (0%) | 0% | 0 | Common Stock | |
| Darius Kharabi | CHIEF BUSINESS OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2024 | 20,500 | 20,500 | - | - | Stock Option (right to buy) | |
| L. Eric Trachtenberg | SEE REMARKS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2024 | 20,500 | 20,500 | - | - | Stock Option (right to buy) | |
| Todd Bazemore | SEE REMARKS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2024 | 29,300 | 29,300 | - | - | Stock Option (right to buy) | |
| Mary Reumuth | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2024 | 4,600 | 67,363 (0%) | 0% | 0 | Common Stock | |
| Darius Kharabi | CHIEF BUSINESS OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2024 | 4,600 | 66,502 (0%) | 0% | 0 | Common Stock | |
| L. Trachtenberg Eric | SEE REMARKS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2024 | 4,600 | 69,293 (0%) | 0% | 0 | Common Stock | |
| Bazemore Todd | SEE REMARKS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2024 | 6,500 | - | 0% | 0 | Common Stock | |
| Mark T. Iwicki | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2023 | 1,512 | 1,512 | - | - | Stock Option (Right to Buy) | |
| R. Kim Brazzell | SEE REMARKS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2023 | 576 | 576 | - | - | Stock Option (Right to Buy) | |
| Todd Bazemore | SEE REMARKS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2023 | 576 | 576 | - | - | Stock Option (Right to Buy) | |
| Eric L. Trachtenberg | SEE REMARKS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2023 | 432 | 432 | - | - | Stock Option (Right to Buy) | |
| Mary Reumuth | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2023 | 432 | 432 | - | - | Stock Option (Right to Buy) | |
| Darius Kharabi | CHIEF BUSINESS OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Mar 2023 | 432 | 432 | - | - | Stock Option (Right to Buy) | |
| Mark T. Iwicki | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 28.54 per share. | 04 Jan 2023 | 198 | 45,966 (0%) | 0% | 28.5 | 5,651 | Common Stock |
| Mark T. Iwicki | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2023 | 41,700 | 46,164 (0%) | 0% | 0 | Common Stock | |
| R. Kim Brazzell | SEE REMARKS | Sale of securities on an exchange or to another person at price $ 28.53 per share. | 04 Jan 2023 | 73 | 18,536 (0%) | 0% | 28.5 | 2,083 | Common Stock |
| R. Kim Brazzell | SEE REMARKS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2023 | 12,800 | 18,609 (0%) | 0% | 0 | Common Stock | |
| Todd Bazemore | SEE REMARKS | Sale of securities on an exchange or to another person at price $ 28.53 per share. | 04 Jan 2023 | 62 | 14,835 (0%) | 0% | 28.5 | 1,769 | Common Stock |
| Todd Bazemore | SEE REMARKS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2023 | 12,800 | 14,897 (0%) | 0% | 0 | Common Stock | |
| Eric L. Trachtenberg | SEE REMARKS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2023 | 9,525 | 11,555 (0%) | 0% | 0 | Common Stock | |
| Eric L. Trachtenberg | SEE REMARKS | Sale of securities on an exchange or to another person at price $ 28.55 per share. | 04 Jan 2023 | 60 | 11,495 (0%) | 0% | 28.6 | 1,713 | Common Stock |
| Mary Reumuth | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2023 | 9,525 | 11,943 (0%) | 0% | 0 | Common Stock | |
| Mary Reumuth | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 28.53 per share. | 04 Jan 2023 | 60 | 11,883 (0%) | 0% | 28.5 | 1,712 | Common Stock |
| Darius Kharabi | CHIEF BUSINESS OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2023 | 9,525 | 15,439 (0%) | 0% | 0 | Common Stock | |
| Marjan Farid | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Oct 2022 | 1,600 | 1,600 | - | - | Stock Option (right to buy) | |
| Mark T. Iwicki | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 6.52 per share. | 26 Oct 2022 | 561 | 4,464 (0%) | 0% | 6.5 | 3,658 | Common Stock |
| R. Kim Brazzell | SEE REMARKS | Sale of securities on an exchange or to another person at price $ 6.51 per share. | 26 Oct 2022 | 261 | 5,809 (0%) | 0% | 6.5 | 1,699 | Common Stock |
| Todd Bazemore | SEE REMARKS | Sale of securities on an exchange or to another person at price $ 6.51 per share. | 26 Oct 2022 | 214 | 2,097 (0%) | 0% | 6.5 | 1,393 | Common Stock |
| Eric L. Trachtenberg | SEE REMARKS | Sale of securities on an exchange or to another person at price $ 6.52 per share. | 26 Oct 2022 | 194 | 2,030 (0%) | 0% | 6.5 | 1,265 | Common Stock |
| Mary Reumuth | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 6.51 per share. | 26 Oct 2022 | 194 | 2,418 (0%) | 0% | 6.5 | 1,263 | Common Stock |
| Mark T. Iwicki | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 0.37 per share. | 27 Jun 2022 | 7,975 | 251,183 (0%) | 0% | 0.4 | 2,951 | Common Stock |
| R. Kim Brazzell | SEE REMARKS | Sale of securities on an exchange or to another person at price $ 0.37 per share. | 27 Jun 2022 | 3,144 | 285,201 (0%) | 0% | 0.4 | 1,163 | Common Stock |
| Todd Bazemore | SEE REMARKS | Sale of securities on an exchange or to another person at price $ 0.37 per share. | 27 Jun 2022 | 3,092 | 115,499 (0%) | 0% | 0.4 | 1,144 | Common Stock |
| Eric L. Trachtenberg | SEE REMARKS | Sale of securities on an exchange or to another person at price $ 0.37 per share. | 27 Jun 2022 | 2,613 | 111,203 (0%) | 0% | 0.4 | 967 | Common Stock |
| Mary Reumuth | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 0.37 per share. | 27 Jun 2022 | 2,613 | 130,595 (0%) | 0% | 0.4 | 967 | Common Stock |
| Andrew I. Koven | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 50,000 | 50,000 | - | - | Stock Option (right to buy) | |
| Gregory D. Perry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| C. Daniel Myers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Howard Rosen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Mark S. Blumenkranz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Robert Paull | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2022 | 40,000 | 40,000 | - | - | Stock Option (right to buy) | |
| Mark T. Iwicki | Director, CHIEF EXECUTIVE OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 775,000 | 775,000 | - | - | Stock Option (right to buy) | |
| Mark T. Iwicki | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 1.30 per share. | 03 Jan 2022 | 9,518 | 259,158 (0%) | 0% | 1.3 | 12,373 | Common Stock |
| R. Kim Brazzell | SEE REMARKS | Sale of securities on an exchange or to another person at price $ 1.30 per share. | 03 Jan 2022 | 3,504 | 288,345 (0%) | 0% | 1.3 | 4,555 | Common Stock |
| R. Kim Brazzell | SEE REMARKS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 238,000 | 238,000 | - | - | Stock Option (right to buy) | |
| Todd Bazemore | SEE REMARKS | Sale of securities on an exchange or to another person at price $ 1.30 per share. | 03 Jan 2022 | 3,454 | 118,591 (0%) | 0% | 1.3 | 4,490 | Common Stock |
| Todd Bazemore | SEE REMARKS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 238,000 | 238,000 | - | - | Stock Option (right to buy) | |
| Eric L. Trachtenberg | SEE REMARKS | Sale of securities on an exchange or to another person at price $ 1.30 per share. | 03 Jan 2022 | 2,850 | 113,816 (0%) | 0% | 1.3 | 3,705 | Common Stock |
| Eric L. Trachtenberg | SEE REMARKS | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 153,000 | 153,000 | - | - | Stock Option (right to buy) | |
| Mary Reumuth | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 1.30 per share. | 03 Jan 2022 | 2,850 | 133,208 (0%) | 0% | 1.3 | 3,705 | Common Stock |
| Mary Reumuth | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Jan 2022 | 153,000 | 153,000 | - | - | Stock Option (right to buy) | |
| Mark S. Blumenkranz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2021 | 42,000 | 42,000 | - | - | Stock Option (right to buy) | |
| Mark S. Blumenkranz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2021 | 38,965 | 38,965 (0%) | 0% | - | Common Stock | |
| Mark S. Blumenkranz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2021 | 5,144,390 | 5,144,390 (13%) | 13% | - | Common Stock | |
| Mark S. Blumenkranz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2021 | 157,765 | 157,765 (0%) | 0% | - | Common Stock | |
| Darius Kharabi | CHIEF BUSINESS OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2021 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Darius Kharabi | CHIEF BUSINESS OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Nov 2021 | 295,657 | 295,657 (0%) | 0% | - | Common Stock | |
| Mark T. Iwicki | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 1.80 per share. | 26 Oct 2021 | 27,598 | 268,676 (0%) | 0% | 1.8 | 49,676 | Common Stock |
| R. Kim Brazzell | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 1.80 per share. | 26 Oct 2021 | 12,757 | 291,849 (0%) | 0% | 1.8 | 22,963 | Common Stock |
| Todd Bazemore | CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 1.80 per share. | 26 Oct 2021 | 12,544 | 122,045 (0%) | 0% | 1.8 | 22,579 | Common Stock |
| Eric L. Trachtenberg | SEE REMARKS | Sale of securities on an exchange or to another person at price $ 1.80 per share. | 26 Oct 2021 | 9,449 | 116,666 (0%) | 0% | 1.8 | 17,008 | Common Stock |
| Hongming Chen | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 1.80 per share. | 26 Oct 2021 | 9,449 | 225,566 (0%) | 0% | 1.8 | 17,008 | Common Stock |
| Hongming Chen | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 1.82 per share. | 26 Oct 2021 | 21,051 | 204,515 (0%) | 0% | 1.8 | 38,313 | Common Stock |
| Mary Reumuth | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 1.80 per share. | 26 Oct 2021 | 9,449 | 136,058 (0%) | 0% | 1.8 | 17,008 | Common Stock |
| C. Daniel Myers | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Oct 2021 | 42,000 | 42,000 | - | - | Stock Option (right to buy) | |
| Hongming Chen | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 5.56 per share. | 29 Jun 2021 | 5,548 | 235,015 (0%) | 0% | 5.6 | 30,847 | Common Stock |
| Mark T. Iwicki | Director, CHIEF EXECUTIVE OFFICER | Sale of securities on an exchange or to another person at price $ 5.77 per share. | 28 Jun 2021 | 7,586 | 296,274 (0%) | 0% | 5.8 | 43,771 | Common Stock |
| R. Kim Brazzell | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 5.77 per share. | 28 Jun 2021 | 3,034 | 300,962 (0%) | 0% | 5.8 | 17,506 | Common Stock |
| Todd Bazemore | CHIEF OPERATING OFFICER | Sale of securities on an exchange or to another person at price $ 5.77 per share. | 28 Jun 2021 | 2,911 | - | 0% | 5.8 | 16,796 | Common Stock |
| Eric L. Trachtenberg | SEE REMARKS | Sale of securities on an exchange or to another person at price $ 5.77 per share. | 28 Jun 2021 | 2,452 | 126,115 (0%) | 0% | 5.8 | 14,148 | Common Stock |
| Hongming Chen | CHIEF SCIENTIFIC OFFICER | Sale of securities on an exchange or to another person at price $ 5.77 per share. | 28 Jun 2021 | 2,452 | 240,563 (0%) | 0% | 5.8 | 14,148 | Common Stock |
| Mary Reumuth | CHIEF FINANCIAL OFFICER | Sale of securities on an exchange or to another person at price $ 5.77 per share. | 28 Jun 2021 | 2,452 | 145,507 (0%) | 0% | 5.8 | 14,148 | Common Stock |
| Andrew I. Koven | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 25,000 | 53,000 (0%) | 0% | 0 | Common Stock | |
| Gregory D. Perry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 20,000 | 40,000 (0%) | 0% | 0 | Common Stock | |
| Howard Rosen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 20,000 | 44,824 (0%) | 0% | 0 | Common Stock | |
| Rajeev Shah | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 20,000 | 20,000 (0%) | 0% | 0 | Common Stock | |
| Gregory Grunberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 20,000 | 40,000 (0%) | 0% | 0 | Common Stock | |
| Robert Paull | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Jun 2021 | 20,000 | 40,000 (0%) | 0% | 0 | Common Stock | |
| Hongming Chen | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Mar 2021 | 9,500 | 53,736 | - | - | Stock Option (right to buy | |
| Hongming Chen | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.30 per share. | 01 Mar 2021 | 9,500 | 243,015 (0%) | 0% | 2.3 | 21,850 | Common Stock |
| Hongming Chen | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Feb 2021 | 47,000 | 63,236 | - | - | Stock Option (right to buy) | |
| Hongming Chen | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.30 per share. | 25 Feb 2021 | 47,000 | 233,515 (0%) | 0% | 2.3 | 108,100 | Common Stock |
| Mark T. Iwicki | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 303,000 | 303,000 | - | - | Stock Option (right to buy) | |
| Mark T. Iwicki | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 76,000 | 303,860 (0%) | 0% | 0 | Common Stock | |
| R. Kim Brazzell | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 27,500 | 303,996 (0%) | 0% | 0 | Common Stock | |
| R. Kim Brazzell | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 110,000 | 110,000 | - | - | Stock Option (right to buy) | |
| Todd Bazemore | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 27,500 | 137,500 (0%) | 0% | 0 | Common Stock | |
| Todd Bazemore | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 110,000 | 110,000 | - | - | Stock Option (right to buy) | |
| Eric L. Trachtenberg | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 90,667 | 90,667 | - | - | Stock Option (right to buy) | |
| Eric L. Trachtenberg | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 22,666 | 128,567 (0%) | 0% | 0 | Common Stock | |
| Hongming Chen | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 90,667 | 90,667 | - | - | Stock Option (right to buy) | |
| Hongming Chen | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 22,666 | 186,515 (0%) | 0% | 0 | Common Stock | |
| Mary Reumuth | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 22,666 | 147,959 (0%) | 0% | 0 | Common Stock | |
| Mary Reumuth | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Jan 2021 | 90,667 | 90,667 | - | - | Stock Option (right to buy) | |
| Mark T. Iwicki | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Oct 2020 | 178,300 | 227,860 (0%) | 0% | 0 | Common Stock | |
| R. Kim Brazzell | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Oct 2020 | 81,000 | 276,496 (0%) | 0% | 0 | Common Stock | |
| Eric L. Trachtenberg | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Oct 2020 | 61,000 | 105,901 (0%) | 0% | 0 | Common Stock | |
| Hongming Chen | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Oct 2020 | 61,000 | 163,849 (0%) | 0% | 0 | Common Stock | |
| Mary Reumuth | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Oct 2020 | 61,000 | 125,293 (0%) | 0% | 0 | Common Stock | |
| Andrew I. Koven | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2020 | 28,000 | 28,000 (0%) | 0% | 0 | Common Stock | |
| Mark T. Iwicki | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2020 | 49,560 | 49,560 (0%) | 0% | 0 | Common Stock | |
| R. Kim Brazzell | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2020 | 19,000 | 195,496 (0%) | 0% | 0 | Common Stock | |
| Gregory D. Perry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2020 | 20,000 | 20,000 (0%) | 0% | 0 | Common Stock | |
| Howard Rosen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2020 | 20,000 | 24,824 (0%) | 0% | 0 | Common Stock | |
| Todd Bazemore | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2020 | 19,000 | 29,000 (0%) | 0% | 0 | Common Stock | |
| Eric L. Trachtenberg | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2020 | 16,000 | 44,901 (0%) | 0% | 0 | Comman Stock | |
| Rajeev Shah | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2020 | 20,000 | 20,000 (0%) | 0% | 0 | Common Stock | |
| Hongming Chen | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2020 | 16,000 | 102,849 (0%) | 0% | 0 | Comman Stock | |
| Mary Reumuth | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2020 | 16,000 | 64,293 (0%) | 0% | 0 | Common Stock | |
| Gregory Grunberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2020 | 20,000 | 20,000 (0%) | 0% | 0 | Common Stock | |
| Robert Paull | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Jun 2020 | 20,000 | 20,000 (0%) | 0% | 0 | Common Stock | |
| Eric L. Trachtenberg | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.19 per share. | 19 Jun 2020 | 28,901 | 28,901 (0%) | 0% | 5.2 | 149,996 | Common Stock |
| Eric L. Trachtenberg | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Jun 2020 | 28,901 | 136,099 | - | - | Stock Option (right to buy) | |
| Mary Reumuth | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jun 2020 | 15,360 | 0 | - | - | Stock Option (right to buy) | |
| Mary Reumuth | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jun 2020 | 11,520 | 0 | - | - | Stock Option (right to buy) | |
| Mary Reumuth | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jun 2020 | 11,520 | 0 | - | - | Stock Option (right to buy) | |
| Mary Reumuth | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.30 per share. | 09 Jun 2020 | 11,520 | 48,293 (0%) | 0% | 2.3 | 26,496 | Common Stock |
| Mary Reumuth | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.30 per share. | 09 Jun 2020 | 15,360 | 36,773 (0%) | 0% | 2.3 | 35,328 | Common Stock |
| Mary Reumuth | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.21 per share. | 09 Jun 2020 | 5,077 | 21,413 (0%) | 0% | 5.2 | 26,451 | Common Stock |
| Mary Reumuth | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.30 per share. | 09 Jun 2020 | 11,520 | 16,336 (0%) | 0% | 2.3 | 26,496 | Common Stock |
| Mary Reumuth | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Jun 2020 | 5,077 | 0 | - | - | Stock Option (right to buy) | |
| Todd Bazemore | Chief Operating Officer | Purchase of securities on an exchange or from another person at price $ 13.50 per share. | 05 Jun 2020 | 2 | 2 (0%) | 0% | 13.5 | 27 | Common Stock |
| Todd Bazemore | Chief Operating Officer | Purchase of securities on an exchange or from another person at price $ 7.60 per share. | 05 Jun 2020 | 40 | 42 (0%) | 0% | 7.6 | 304 | Common Stock |
| Todd Bazemore | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2020 | 81,000 | 110,000 (0%) | 0% | 0 | Common Stock | |
| R. Kim Brazzell | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Apr 2020 | 1,880 | 0 | - | - | Stock Option (right to buy) | |
| R. Kim Brazzell | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.34 per share. | 09 Apr 2020 | 47,644 | 176,496 (0%) | 0% | 3.3 | 159,131 | Common Stock |
| R. Kim Brazzell | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.30 per share. | 09 Apr 2020 | 18,247 | 128,852 (0%) | 0% | 2.3 | 41,968 | Common Stock |
| R. Kim Brazzell | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.68 per share. | 09 Apr 2020 | 1,880 | 110,605 (0%) | 0% | 0.7 | 1,278 | Common Stock |
| R. Kim Brazzell | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Apr 2020 | 47,644 | 13,508 | - | - | Stock Option (right to buy) | |
| R. Kim Brazzell | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Apr 2020 | 18,247 | 0 | - | - | Stock Option (right to buy) | |
| Hongming Chen | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Mar 2020 | 31,000 | 75,236 | - | - | Stock Option (right to buy) | |
| Hongming Chen | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.30 per share. | 30 Mar 2020 | 31,000 | 86,849 (0%) | 0% | 2.3 | 71,300 | Common Stock |
| Todd Bazemore | Chief Operating Officer | Purchase of securities on an exchange or from another person at price $ 5.75 per share. | 16 Mar 2020 | 10,000 | 10,000 (0%) | 0% | 5.8 | 57,500 | Common Stock |
| Rajeev Shah | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 7.89 per share. | 13 Mar 2020 | 6,337,135 | 10,874,613 (29%) | 17% | 7.9 | 49,999,995 | Common Stock |
| Gregory Grunberg | Director | Purchase of securities on an exchange or from another person at price $ 7.89 per share. | 13 Mar 2020 | 2,534,854 | 2,534,854 (6%) | 6% | 7.9 | 19,999,998 | Common Stock |
| Mark T. Iwicki | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2020 | 365,000 | 365,000 | - | - | Stock Option (right to buy) | |
| R. Kim Brazzell | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2020 | 120,000 | 120,000 | - | - | Stock Option (right to buy) | |
| Todd Bazemore | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2020 | 120,000 | 120,000 | - | - | Stock Option (right to buy) | |
| Eric L. Trachtenberg | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2020 | 120,000 | 120,000 | - | - | Stock Option (right to buy) | |
| Hongming Chen | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2020 | 120,000 | 120,000 | - | - | Stock Option (right to buy) | |
| Mary Reumuth | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2020 | 120,000 | 120,000 | - | - | Stock Option (right to buy) | |
| Todd Bazemore | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Oct 2019 | 175,000 | 175,000 | - | - | Stock Option (right to buy) | |
| Eric L. Trachtenberg | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Oct 2019 | 100,000 | 100,000 | - | - | Stock Option (right to buy) | |
| Howard Rosen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2019 | 2,880 | 0 | - | - | Stock Option (right to buy) | |
| Howard Rosen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.68 per share. | 19 Aug 2019 | 2,880 | 2,880 (0%) | 0% | 0.7 | 1,958 | Common Stock |
| Howard Rosen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.47 per share. | 19 Aug 2019 | 1,944 | 4,824 (0%) | 0% | 0.5 | 914 | Common Stock |
| Howard Rosen | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Aug 2019 | 1,944 | 0 | - | - | Stock Option (right to buy) | |
| Andrew I. Koven | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2019 | 21,000 | 21,000 | - | - | Stock Option (right to buy) | |
| Gregory D. Perry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2019 | 21,000 | 21,000 | - | - | Stock Option (right to buy) | |
| Howard Rosen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2019 | 21,000 | 21,000 | - | - | Stock Option (right to buy) | |
| Rajeev Shah | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2019 | 21,000 | 21,000 | - | - | Stock Option (right to buy) | |
| Gregory Grunberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2019 | 21,000 | 21,000 | - | - | Stock Option (right to buy) | |
| Robert Paull | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2019 | 21,000 | 21,000 | - | - | Stock Option (right to buy) | |
| Howard Rosen | Director | Purchase of securities on an exchange or from another person at price $ 5.42 per share. | 30 May 2019 | 5,000 | 8,240 (0%) | 0% | 5.4 | 27,100 | Common stock |
| Mark T. Iwicki | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2019 | 460,000 | 460,000 | - | - | Stock Option (right to buy) | |
| R. Kim Brazzell | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2019 | 150,000 | 150,000 | - | - | Stock Option (right to buy) | |
| Todd Bazemore | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2019 | 175,000 | 175,000 | - | - | Stock Option (right to buy) | |
| Eric L. Trachtenberg | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2019 | 165,000 | 165,000 | - | - | Stock Option (right to buy) | |
| Hongming Chen | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2019 | 150,000 | 150,000 | - | - | Stock Option (right to buy) | |
| Mary Reumuth | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2019 | 150,000 | 150,000 | - | - | Stock Option (right to buy) | |
| Gregory Grunberg | Director | Purchase of securities on an exchange or from another person at price $ 8.25 per share. | 05 Oct 2018 | 606,060 | 2,877,006 (7%) | 1% | 8.3 | 4,999,995 | Common Stock |
| Rajeev Shah | Director, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 8.25 per share. | 03 Oct 2018 | 2,424,242 | 4,537,478 (12%) | 9% | 8.3 | 19,999,997 | Common Stock |
| Andrew I. Koven | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2018 | 12,960 | 12,960 | - | - | Stock Option (right to buy) | |
| Robert S. Langer | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2018 | 12,960 | 12,960 | - | - | Stock Option (right to buy) | |
| Howard Rosen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2018 | 12,960 | 12,960 | - | - | Stock Option (right to buy) | |
| Rajeev Shah | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2018 | 12,960 | 12,960 | - | - | Stock Option (right to buy) | |
| Gregory Grunberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2018 | 12,960 | 12,960 | - | - | Stock Option (right to buy) | |
| Paulina Hill | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2018 | 12,960 | 12,960 | - | - | Stock Option (right to buy) | |
| Robert Paull | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2018 | 12,960 | 12,960 | - | - | Stock Option (right to buy) | |
| Robert Paull | Director | Other type of transaction at price $ 0.00 per share. | 18 May 2018 | 597 | 597 (0%) | 0% | 0 | Common Stock | |
| Robert Paull | Director | Other type of transaction at price $ 0.00 per share. | 18 May 2018 | 477 | 1,074 (0%) | 0% | 0 | Common Stock | |
| Robert Paull | Director | Other type of transaction at price $ 0.00 per share. | 18 May 2018 | 1,287 | 2,361 (0%) | 0% | 0 | Common Stock | |
| Eric L. Trachtenberg | General Counsel and Secretary | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Apr 2018 | 150,000 | 150,000 | - | - | Stock Option (right to buy) | |
| Gregory D. Perry | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2018 | 25,920 | 25,920 | - | - | Stock Option (right to buy) | |
| Hongming Chen | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.24 per share. | 28 Feb 2018 | 5,769 | 55,849 (0%) | 0% | 2.2 | 12,923 | Common Stock |
| Hongming Chen | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2018 | 5,769 | 0 | - | - | Stock Option (right to buy) | |
| Hongming Chen | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2018 | 4,000 | 106,236 | - | - | Stock Option (right to buy) | |
| Hongming Chen | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.30 per share. | 28 Feb 2018 | 4,000 | 50,080 (0%) | 0% | 2.3 | 9,200 | Common Stock |
| Mark T. Iwicki | Director, Chief Executive Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2018 | 230,000 | 230,000 | - | - | Stock Option (right to buy) | |
| R. Kim Brazzell | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2018 | 70,000 | 70,000 | - | - | Stock Option (right to buy) | |
| Todd Bazemore | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2018 | 25,000 | 25,000 | - | - | Stock Option (right to buy) | |
| Hongming Chen | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2018 | 70,000 | 70,000 | - | - | Stock Option (right to buy) | |
| Mary Reumuth | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2018 | 70,000 | 70,000 | - | - | Stock Option (right to buy) | |
| Michele LaRussa | Sr. VP, Regulatory and Quality | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Feb 2018 | 8,000 | 8,000 | - | - | Stock Option (right to buy) | |
| Todd Bazemore | Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2017 | 172,000 | 172,000 | - | - | Stock Option (right to buy) | |
| Andrew I. Koven | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Sep 2017 | 25,920 | 25,920 | - | - | Stock Option (right to buy) | |
| R. Kim Brazzell | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.68 per share. | 11 Aug 2017 | 36,094 | 36,094 (0%) | 0% | 0.7 | 24,544 | Common Stock |
| R. Kim Brazzell | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2017 | 12,150 | 149,985 | - | - | Stock Option (right to buy) | |
| R. Kim Brazzell | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2017 | 44,313 | 18,247 | - | - | Stock Option (right to buy) | |
| R. Kim Brazzell | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2017 | 16,168 | 1,880 | - | - | Stock Option (right to buy) | |
| R. Kim Brazzell | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2017 | 36,094 | 0 | - | - | Stock Option (right to buy) | |
| R. Kim Brazzell | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.34 per share. | 11 Aug 2017 | 12,150 | 108,725 (0%) | 0% | 3.3 | 40,581 | Common Stock |
| R. Kim Brazzell | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.30 per share. | 11 Aug 2017 | 44,313 | 96,575 (0%) | 0% | 2.3 | 101,920 | Common Stock |
| R. Kim Brazzell | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.68 per share. | 11 Aug 2017 | 16,168 | 52,262 (0%) | 0% | 0.7 | 10,994 | Common Stock |
| Robert Tepper | None | 25 Jul 2017 | 2,265,764 | 0 | - | - | Series B Preferred Stock | ||
| Robert Tepper | None | 25 Jul 2017 | 173,611 | 0 | - | - | Series B Preferred Stock Warrant (right to buy) | ||
| Robert Tepper | None | 25 Jul 2017 | 33,333 | 33,333 | - | - | Common Stock Warrant (right to buy) | ||
| Robert Tepper | None | 25 Jul 2017 | 1,621,092 | 1,621,092 (6%) | 6% | 0 | Common Stock | ||
| Robert Tepper | None | 25 Jul 2017 | 3,677,374 | 0 | - | - | Series Seed Preferred Stock | ||
| Robert Tepper | None | 25 Jul 2017 | 2,500,000 | 0 | - | - | Series A Preferred Stock | ||
| Rajeev Shah | None | 25 Jul 2017 | 3,819,444 | 0 | - | - | Series B Preferred Stock | ||
| Rajeev Shah | None | 25 Jul 2017 | 1,579,903 | 1,579,903 (6%) | 6% | 0 | Common Stock | ||
| Rajeev Shah | None | Purchase of securities on an exchange or from another person at price $ 15.00 per share. | 25 Jul 2017 | 533,333 | 2,113,236 (9%) | 2% | 15 | 7,999,995 | Common Stock |
| Rajeev Shah | None | 25 Jul 2017 | 4,409,170 | 0 | - | - | Series C Preferred Stock | ||
| Gregory Grunberg | None | 25 Jul 2017 | 2,055,946 | 2,055,946 (8%) | 8% | 0 | Common Stock | ||
| Gregory Grunberg | None | 25 Jul 2017 | 10,707,985 | 0 | - | - | Series C Preferred Stock | ||
| Gregory Grunberg | None | Purchase of securities on an exchange or from another person at price $ 15.00 per share. | 25 Jul 2017 | 215,000 | 2,270,946 (9%) | 0% | 15 | 3,225,000 | Common Stock |
| Robert Paull | None | 25 Jul 2017 | 31,494 | 0 | - | - | Series C Preferred Stock | ||
| Robert Paull | None | 25 Jul 2017 | 16,152 | 16,152 | - | - | Common Stock Warrant (right to buy) | ||
| Robert Paull | None | 25 Jul 2017 | 1,204,937 | 1,204,937 (5%) | 5% | 0 | Common Stock | ||
| Robert Paull | None | 25 Jul 2017 | 84,130 | 0 | - | - | Series B Preferred Stock Warrant (right to buy) | ||
| Robert Paull | None | 25 Jul 2017 | 1,666,666 | 0 | - | - | Series A Preferred Stock | ||
| Robert Paull | None | 25 Jul 2017 | 3,677,373 | 0 | - | - | Series Seed Preferred Stock | ||
| Robert Paull | None | 25 Jul 2017 | 900,146 | 0 | - | - | Series B Preferred Stock | ||
| Mark T. Iwicki | Director, Chief Executive Officer, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jul 2017 | 78,632 | 78,632 | - | - | Stock Option (right to buy) | |
| Robert S. Langer | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jul 2017 | 12,960 | 12,960 | - | - | Stock Option (right to buy) | |
| Robert Tepper | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jul 2017 | 12,960 | 12,960 | - | - | Stock Option (right to buy) | |
| R. Kim Brazzell | Chief Medical Officer, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jul 2017 | 47,142 | 47,142 | - | - | Stock Option (right to buy) | |
| Howard Rosen | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jul 2017 | 12,960 | 12,960 | - | - | Stock Option (right to buy) | |
| Rajeev Shah | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jul 2017 | 12,960 | 12,960 | - | - | Stock Option (right to buy) | |
| Hongming Chen | Chief Scientific Officer, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jul 2017 | 28,800 | 28,800 | - | - | Stock Option (right to buy) | |
| Mary Reumuth | Chief Financial Officer, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jul 2017 | 28,973 | 28,973 | - | - | Stock Option (right to buy) | |
| Gregory Grunberg | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jul 2017 | 12,960 | 12,960 | - | - | Stock Option (right to buy) | |
| Paulina Hill | None | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jul 2017 | 12,960 | 12,960 | - | - | Stock Option (right to buy) | |
| Robert Paull | Director, Ten Percent Owner | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jul 2017 | 12,960 | 12,960 | - | - | Stock Option (right to buy) |